SEC Company Response from Eloxx Pharmaceuticals, Inc. (ELOX) (CIK 0001035354) — Aug 26, 2021
Eloxx Pharmaceuticals, Inc. (ELOX) (CIK 0001035354)
Date: Aug. 26, 2021 · CIK: 0001035354 · Accession: 0001104659-21-109793
AI Filing Summary & Sentiment
File numbers found in text: 333-258994
Letter
Eloxx Pharmaceuticals, Inc.
480 Arsenal Way
Watertown, MA 02472
August 26, 2021
Via EDGAR Transmission
Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4720
100 F Street, N.E.
Washington, D.C. 20549
Re: ELOXX PHARMACEUTICALS, INC.
Registration Statement on Form S-3 (Registration No. 333-258994)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (Registration No. 333-258994) (the “Registration Statement”) of Eloxx Pharmaceuticals, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:30 p.m., Eastern Time, on August 30, 2021, or at such later time as the Company or its counsel may orally request via telephone call to the staff. Please contact Wesley C. Holmes of Latham & Watkins LLP, counsel to the Company, at (617) 948-6027, or in his absence, Peter Handrinos at (617) 948-6060, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Very truly yours,
ELOXX PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Eloxx
Pharmaceuticals, Inc.
480 Arsenal Way
Watertown,
MA 02472
August 26, 2021
Via EDGAR Transmission
Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4720
100 F Street, N.E.
Washington, D.C. 20549
Re: ELOXX PHARMACEUTICALS, INC.
Registration Statement on Form
S-3 (Registration No. 333-258994)
Ladies and Gentlemen:
In accordance with Rule 461
under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form
S-3 (Registration No. 333-258994) (the “Registration Statement”) of Eloxx Pharmaceuticals, Inc. (the “Company”).
We respectfully request that the Registration Statement become effective as of 4:30 p.m., Eastern Time, on August 30, 2021, or at such
later time as the Company or its counsel may orally request via telephone call to the staff. Please contact Wesley C. Holmes of Latham
& Watkins LLP, counsel to the Company, at (617) 948-6027, or in his absence, Peter Handrinos at (617) 948-6060, to provide notice
of effectiveness, or if you have any other questions or concerns regarding this matter.
Very truly yours,
ELOXX PHARMACEUTICALS, INC.
By:
/s/ Sumit Aggarwal
Name:
Sumit Aggarwal
Title:
Chief Executive Officer
cc:
Daniel E. Geffken, Eloxx Pharmaceuticals, Inc.
Peter N. Handrinos, Latham & Watkins LLP
Wesley C. Holmes, Latham & Watkins LLP